Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2020

View Archived Issues

X chromosome is finished

Metabolic reprogramming promotes ADPKD cystogenesis

Phase III data presented for SCT-800 in severe hemophilia A patients

AZP-2006 studied in phase II for progressive supranuclear palsy

TIE2 IgG monoclonal agonistic antibody PMC-403 stabilizes vessels to enhance antitumor therapy

First-in-human study examines CAR-37 T cells in relapsed/refractory CD37+ hematologic malignancies

Novel engineered mouse model of GvHD

Discovery of novel anti-ILT2 monoclonal antibody, BND-22

Agios Pharmaceuticals presents Mat2A inhibitors

Newave Pharmaceutical divulges Bcl-2 inhibitors

CytoDyn presents safety data from phase II COVID-19 trial of leronlimab

FutureChem identifies FOLH1-binding radiopharmaceuticals

FORMA Therapeutics synthesizes USP9X inhibitors

Shanghai Dude Medical Science and Technology discovers TRK inhibitors

IMM-124E shows neutralizing activity against SARS-CoV-2

First patient dosed in phase II study of taletrectinib in NSCLC with ROS1 fusion

FDA places partial clinical hold on PRS-343

Researchers develop mouse model for imaging of Ca2+ changes in platelets

TNFR2 agonistic and antagonistic antibodies developed at BioInvent for treating solid tumors

FDA approves Qutenza for neuropathic pain associated with DPN of the feet

Phase III Measure Up 2 study of Rinvoq in atopic dermatitis meets primary and secondary endpoints

CTA cleared for phase I/IIa study of LUNAR-COV19 vaccine candidate

Bristol-Myers Squibb begins phase I/II study of BMS-986315 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...